Skip to main content

Advertisement

Figure 7 | Molecular Autism

Figure 7

From: Antipurinergic therapy corrects the autism-like features in the Fragile X (Fmr1 knockout) mouse model

Figure 7

Cytoscape visualization of the metabolic pathways altered by antipurinergic therapy in the Fragile X mouse model. Twenty-six of the 60 biochemical pathways interrogated in our metabolomic analysis are illustrated. See Additional file 1: Tables S2 and S3 for complete listing of pathways and discriminating metabolites, respectively. The fractional contribution of each of the top 20 pathways altered by suramin treatment is indicated as a percentage of the total variable importance in projection (VIP) score in the black circles. Purine metabolism contributed 20% of the top ranked VIP scores, followed by fatty acid oxidation (12%), eicosanoids (11%), gangliosides (10%), phospholipids (9%), and 15 other biochemical pathways as indicated. Smaller circles indicate the metabolites in each pathway, quantified by z-score. Metabolites in red were increased. Metabolites in green were decreased by treatment with suramin. Age 25 weeks, N = 9-11 per group.

Back to article page